New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut

2010 ◽  
Vol 17 (17) ◽  
pp. 1851-1857 ◽  
Author(s):  
G. Fiorino ◽  
W. Fries ◽  
S.A. De La Rue ◽  
A.C. Malesci ◽  
A. Repici ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
New Drug ◽  
Inflammatory Bowel

scholarly journals Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy

Nanomaterials ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 2460
Author(s):  
Eden Mariam Jacob ◽  
Ankita Borah ◽  
Sindhu C Pillai ◽  
D. Sakthi Kumar
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Bowel Disease ◽  
Oral Delivery ◽  
Drug Delivery Systems ◽  
Genetic Defect ◽  
Delivery Systems ◽  
Conventional Drug ◽  
Inflammatory Bowel

The human intestine, which harbors trillions of symbiotic microorganisms, may enter into dysbiosis when exposed to a genetic defect or environmental stress. The naissance of chronic inflammation due to the battle of the immune system with the trespassing gut bacteria leads to the rise of inflammatory bowel disease (IBD). Though the genes behind the scenes and their link to the disease are still unclear, the onset of IBD occurs in young adults and has expanded from the Western world into the newly industrialized countries. Conventional drug deliveries depend on a daily heavy dosage of immune suppressants or anti-inflammatory drugs targeted for the treatment of two types of IBD, ulcerative colitis (UC) and Crohn’s disease (CD), which are often associated with systemic side effects and adverse toxicities. Advances in oral delivery through nanotechnology seek remedies to overcome the drawbacks of these conventional drug delivery systems through improved drug encapsulation and targeted delivery. In this review, we discuss the association of genetic factors, the immune system, the gut microbiome, and environmental factors like diet in the pathogenesis of IBD. We also review the various physiological concerns required for oral delivery to the gastrointestinal tract (GIT) and new strategies in nanotechnology-derived, colon-targeting drug delivery systems.

scholarly journals RECENT APPROACHES INVOLVED IN COLONIC DRUG TARGETING FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A REVIEW

2021 ◽  
pp. 40-46
Author(s):  
SWAMINATHAN V. ◽  
VAIYANA RAJESH C.
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Drug Targeting ◽  
Drug Delivery Systems ◽  
Adverse Reactions ◽  
Delivery Systems ◽  
Systemic Absorption ◽  
Conventional Drug ◽  
Inflammatory Bowel

The objective of the review is to present the contemporary approaches involved in colonic drug targeting for the therapy of inflammatory bowel disease (IBD). The adverse reactions and side-effects of the conventional drug delivery systems are largely on account of the systemic absorption of the drugs from the small intestine. Moreover, in current drug delivery systems, the drug has to be frequently administered and also in larger doses which greatly reduces patient compliance. Various approaches which are being described here mainly target the colonic region specifically for improved therapy of IBD, by increasing localization and accessibility of the drug to the target site. Also, these approaches will result in the reduction of dose and minimization of adverse effects combined with the use of conventional drug delivery systems.

scholarly journals Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Caifang Gao ◽  
Lijuan Liu ◽  
Yangyang Zhou ◽  
Zhaoxiang Bian ◽  
Shengpeng Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Chinese Medicine ◽  
Bowel Disease ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Inflammatory Bowel ◽  
Novel Drug
Sign in / Sign up

Export Citation Format

Share Document